Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index; 10 of the 61 sources its claims cite were checked for support.

Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies

Open access

Abstract

Superagonistic CD28 antibodies (CD28SAs) activate T lymphocytes without concomitant perturbation of the TCR/CD3-complex. In rodents these reagents induce the preferential expansion of regulatory T cells and can be used for the treatment of autoimmune diseases. Unexpectedly, the humanized CD28 superagonist TGN1412 caused severe and life threatening adverse effects during a recently conducted phase I clinical trail. The underlying molecular mechanisms are as yet unclear. We show that TGN1412 as well as the commercially available CD28 superagonist ANC28.1 induce a delayed but extremely sustained calcium response in human naïve and memory CD4+ T cells but not in cynomolgus T lymphocytes. The sustained Ca++-signal was associated with the activation of multiple intracellular signaling pathways and together these events culminated in the rapid de novo synthesis of high amounts of pro-inflammatory cytokines, most notably IFN-gamma and TNF-alpha. Importantly, sustained transmembranous calcium flux, activation of Src-kinases as well as activation of PI3K were found to be absolutely required for CD28SA-mediated production of IFN-gamma and IL-2. Collectively, our data suggest a molecular basis for the severe side effects caused by TGN1412 and impinge upon the relevance of non-human primates as preclinical models for reagents that are supposed to modify the function of human T cells.

Overview

CoChat Summary

TL;DR

Two anti-human CD28 superagonists, TGN1412 and ANC28.1, induce a delayed but extremely sustained calcium signal in human CD4+ T cells that drives multiple signaling pathways and rapid pro-inflammatory cytokine production. This response is not reproduced in cynomolgus or rhesus monkey T cells despite conserved CD28 extracellular domains, suggesting a molecular basis for TGN1412’s severe clinical side effects and questioning non-human primates as preclinical models.

Key findings

  • ANC28.1 and TGN1412 induced a sustained Ca++ signal in human naïve and memory CD4+ T cells that lasted for more than six hours without significant decrease; conventional CD28 mAbs did not induce detectable Ca++ flux.
  • CD28SA stimulation activated multiple pathways (Erk1/2, JNK, p38, AKT, GSK3β-1, NF-ATc1, IκBα) and led to rapid de novo cytokine synthesis; IFN-γ was detectable in culture supernatant already 90–120 minutes after stimulation.
  • IFN-γ and IL-2 production required transmembranous calcium flux, Src-kinase activity, PI3K activity, and calcineurin/NF-AT signaling; EGTA, cycloheximide, PP2, cyclosporin A, Wortmannin, and LY294002 each abrogated these responses.
  • Despite complete conservation of CD28 extracellular and cytoplasmic domains between human, rhesus, and cynomolgus monkeys, TGN1412 induced only a very low calcium signal in monkey T cells; sequencing of 14 rhesus and 11 cynomolgus monkeys found three non-conservative amino acid exchanges in the transmembrane region and one in the leader sequence.

Methods

  • Human T cells were purified from healthy volunteers; monkey T cells were purified from Macaca mulatta and Macaca fascicularis blood.
  • Proliferation was measured by [3H]-thymidine incorporation; signaling was assessed by phosphospecific western blotting; calcium responses were measured by Indo-1 flow cytometry and Fura2 live video microscopy; cytokines were measured by cytometric bead arrays and ELISA.
  • CD28 cDNAs from 14 rhesus and 11 cynomolgus monkeys were sequenced and compared with human CD28; TGN1412 binding and T cell subsets were analyzed by FACS.

Limitations

  • The paper states that it is unclear how transmembrane calcium flux is induced and maintained upon CD28SA stimulation, which kinase phosphorylates LAT, and whether PI3K regulates IL-2/IFN-γ via AKT; it also cannot exclude differences in CD28 microcluster assembly or dynamics.
  • The paper notes that CD28SAs do not fully activate human T cells, as β1/β2-integrin activation, F-actin formation, and cell migration were not observed.
  • Evident from the text: the mechanistic work is primarily in vitro with human and monkey T cells, and the proposed link to TGN1412’s clinical cytokine storm is inferential rather than directly demonstrated in vivo.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0001708

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 The CD28 superagonist ANC28.1 induces polyclonal T cell activation in vitro and leads to ZAP70 independent phosphorylation of LAT and PLCγ1. (A) 5×104 freshly prepared human T cells per well were seeded in 96-well plates and treated with the indicated combinations of antibodies or were incubated in medium as a control. 72 hours after stimulation, cultures were pulsed with 3H-thymidine for 6 hours and harvested thereafter. Note that ANC28.1 only induces polyclonal T cell proliferation when applied in soluble form (in this case 10 µg/ml of soluble ANC28.1 were crosslinked in solution with 20 µg/ml of polyclonal goat-anti-mouse antiserum). All other stimulations (including stimulation of T cells with CD3ε mAb and ANC28.1; very right bar in Fig. 1A) were performed in wells that were pre-coated with polyclonal goat anti-mouse antiserum. Shown data are representative for at least 6 independently performed experiments. (B) 1×106 freshly prepared human T cells/lane were stimulated in solution with 10 µg/ml ANC28.1 followed by crosslinking with 20 µg/ml polyclonal goat anti-mouse antiserum for the indicated periods of time. As a control, cells were activated with a 1∶50 v/v dilution of ascites fluid of CD3ε mAb MEM92 (IgM) or were left untreated. Cell lysates were processed for western blotting using the indicated phosphospecific antibodies (Y319 of ZAP70, Y171 of LAT, and Y783 of PLCγ1). Western blotting using an anti-actin antibody was performed as loading control.
Figure 1 The CD28 superagonist ANC28.1 induces polyclonal T cell activation in vitro and leads to ZAP70 independent phosphorylation of LAT and PLCγ1. (A) 5×104 freshly prepared human T cells per well were seeded in 96-well plates and treated with the indicated combinations of antibodies or were incubated in medium as a control. 72 hours after stimulation, cultures were pulsed with 3H-thymidine for 6 hours and harvested thereafter. Note that ANC28.1 only induces polyclonal T cell proliferation when applied in soluble form (in this case 10 µg/ml of soluble ANC28.1 were crosslinked in solution with 20 µg/ml of polyclonal goat-anti-mouse antiserum). All other stimulations (including stimulation of T cells with CD3ε mAb and ANC28.1; very right bar in Fig. 1A) were performed in wells that were pre-coated with polyclonal goat anti-mouse antiserum. Shown data are representative for at least 6 independently performed experiments. (B) 1×106 freshly prepared human T cells/lane were stimulated in solution with 10 µg/ml ANC28.1 followed by crosslinking with 20 µg/ml polyclonal goat anti-mouse antiserum for the indicated periods of time. As a control, cells were activated with a 1∶50 v/v dilution of ascites fluid of CD3ε mAb MEM92 (IgM) or were left untreated. Cell lysates were processed for western blotting using the indicated phosphospecific antibodies (Y319 of ZAP70, Y171 of LAT, and Y783 of PLCγ1). Western blotting using an anti-actin antibody was performed as loading control.CC BY · PubMed Central
Figure 2 Induction of sustained calcium flux by human CD28 superagonistic antibody ANC28.1. (A) 1×106 freshly prepared Indo-1 loaded human T cells were stimulated with either a 1∶50 v/v dilution of ascites fluid of CD3 mAb MEM92 (orange triangle), 10 µg/ml conventional CD28 mAb (CD28.2; blue triangle) followed by crosslinking with 20 µg/ml polyclonal goat anti-mouse antiserum (black triangle) or 10 µg/ml ANC28.1 (red triangle) followed by crosslinking with 20 µg/ml polyclonal goat anti-mouse antiserum (black triangle). Induction of the Ca++-response was monitored for approximately 75 minutes. Note that using another conventional anti-CD28 mAb (248.23.2; with or without crosslinking) no Ca++-flux was induced as well (data not shown). (B) Untreated (untreated T cells) or 2AD2A2 pre-treated (TCRdull T cells) human T cells were stimulated with ANC28.1 (red triangles) and subsequently crosslinked (black triangles) as described in (A) and induction of the Ca++-response was monitored for the indicated periods of time. To confirm proper loading of the cells with Indo-1, the Ca++-ionophore Ionomycin (10 µg/ml) was added at the end of the experiment (unfilled triangle). (C) Cells were treated with ANC28.1 (red triangles) followed by crosslinking (black triangles) as described in (A) in the absence (no inhibitor) or presence of the PI3-kinase inhibitor Wortmannin (0.2 µM) or the Src-kinase inhibitor PP2 (10 µM). (D) CD3 (orange triangle) or ANC28.1 (red triangle) stimulation plus crosslinking (black triangle) was performed as described in (A) in culture medium that was supplemented with 1 mM EGTA to chelate extracellular Ca++ ions (solid arrow). At the indicated time points CaCl2 was added at a final concentration of 2 mM (dashed arrow). (E) Cells were treated with ANC28.1 as described in Fig. 1A. Additionally, at about 1 h of Ca-flux, a 1∶50 v/v dilution of ascites fluid of CD3 mAb MEM92 (orange triangle) was added. (F) CD8+, CD4+, CD4+/CD45RA+ naïve, and CD4+/CD45RO+ memory T lymphocytes were treated with ANC28.1 as described in (A) and induction of the Ca++-response was monitored for approximately 150 minutes.
Figure 2 Induction of sustained calcium flux by human CD28 superagonistic antibody ANC28.1. (A) 1×106 freshly prepared Indo-1 loaded human T cells were stimulated with either a 1∶50 v/v dilution of ascites fluid of CD3 mAb MEM92 (orange triangle), 10 µg/ml conventional CD28 mAb (CD28.2; blue triangle) followed by crosslinking with 20 µg/ml polyclonal goat anti-mouse antiserum (black triangle) or 10 µg/ml ANC28.1 (red triangle) followed by crosslinking with 20 µg/ml polyclonal goat anti-mouse antiserum (black triangle). Induction of the Ca++-response was monitored for approximately 75 minutes. Note that using another conventional anti-CD28 mAb (248.23.2; with or without crosslinking) no Ca++-flux was induced as well (data not shown). (B) Untreated (untreated T cells) or 2AD2A2 pre-treated (TCRdull T cells) human T cells were stimulated with ANC28.1 (red triangles) and subsequently crosslinked (black triangles) as described in (A) and induction of the Ca++-response was monitored for the indicated periods of time. To confirm proper loading of the cells with Indo-1, the Ca++-ionophore Ionomycin (10 µg/ml) was added at the end of the experiment (unfilled triangle). (C) Cells were treated with ANC28.1 (red triangles) followed by crosslinking (black triangles) as described in (A) in the absence (no inhibitor) or presence of the PI3-kinase inhibitor Wortmannin (0.2 µM) or the Src-kinase inhibitor PP2 (10 µM). (D) CD3 (orange triangle) or ANC28.1 (red triangle) stimulation plus crosslinking (black triangle) was performed as described in (A) in culture medium that was supplemented with 1 mM EGTA to chelate extracellular Ca++ ions (solid arrow). At the indicated time points CaCl2 was added at a final concentration of 2 mM (dashed arrow). (E) Cells were treated with ANC28.1 as described in Fig. 1A. Additionally, at about 1 h of Ca-flux, a 1∶50 v/v dilution of ascites fluid of CD3 mAb MEM92 (orange triangle) was added. (F) CD8+, CD4+, CD4+/CD45RA+ naïve, and CD4+/CD45RO+ memory T lymphocytes were treated with ANC28.1 as described in (A) and induction of the Ca++-response was monitored for approximately 150 minutes.CC BY · PubMed Central
Figure 3 Sustained calcium flux, T cell proliferation, and T cell signaling upon TGN1412 treatment. (A) Freshly isolated human T cells were treated as described in Fig. 2 using the superagonistic CD28 specific mAb TGN1412 (10 µg/ml; red triangle). For crosslinking, 20 µg/ml of monoclonal mouse anti-human IgG4 was used (black triangle) and induction of the Ca++-response was monitored. (B) 5×104 freshly prepared human T-cells/96-well were stimulated with the indicated concentrations of ANC28.1 or TGN1412 or were left untreated as a control. For crosslinking of ANC28.1, a polyclonal goat anti-mouse antiserum was used and crosslinking of TGN1412 was performed as described in (A). Concentrations for crosslinking were the following: 0.1–1.25 µg/ml primary Ab+2.5 µg/ml crosslinker; 2.5 µg/ml primary Ab+5 µg/ml crosslinker; 5 µg/ml primary Ab+10 µg/ml crosslinker; 10 µg/ml primary Ab+20 µg/ml crosslinker. 72 hours after stimulation, cultures were pulsed with 3H-thymidine for 6 hours, then harvested and proliferation analyzed by counts per minute [cpm]. (C) 1×106 freshly prepared human T cells/lane were left untreated or were stimulated with 10 µg/ml ANC28.1 (first and third panel) followed by crosslinking with 20 µg/ml polyclonal goat anti-mouse antiserum or with 10 µg/ml TGN1412 (right panel) followed by crosslinking as described in (A) for the indicated periods of time. As a control, cells were activated with a 1∶50 dilution of ascites fluid of CD3 mAb MEM92 (second panel). Postnuclear lysates were processed for western blotting using the indicated phosphospecific antibodies. Western blotting using an anti-actin antibody was performed as loading control.
Figure 3 Sustained calcium flux, T cell proliferation, and T cell signaling upon TGN1412 treatment. (A) Freshly isolated human T cells were treated as described in Fig. 2 using the superagonistic CD28 specific mAb TGN1412 (10 µg/ml; red triangle). For crosslinking, 20 µg/ml of monoclonal mouse anti-human IgG4 was used (black triangle) and induction of the Ca++-response was monitored. (B) 5×104 freshly prepared human T-cells/96-well were stimulated with the indicated concentrations of ANC28.1 or TGN1412 or were left untreated as a control. For crosslinking of ANC28.1, a polyclonal goat anti-mouse antiserum was used and crosslinking of TGN1412 was performed as described in (A). Concentrations for crosslinking were the following: 0.1–1.25 µg/ml primary Ab+2.5 µg/ml crosslinker; 2.5 µg/ml primary Ab+5 µg/ml crosslinker; 5 µg/ml primary Ab+10 µg/ml crosslinker; 10 µg/ml primary Ab+20 µg/ml crosslinker. 72 hours after stimulation, cultures were pulsed with 3H-thymidine for 6 hours, then harvested and proliferation analyzed by counts per minute [cpm]. (C) 1×106 freshly prepared human T cells/lane were left untreated or were stimulated with 10 µg/ml ANC28.1 (first and third panel) followed by crosslinking with 20 µg/ml polyclonal goat anti-mouse antiserum or with 10 µg/ml TGN1412 (right panel) followed by crosslinking as described in (A) for the indicated periods of time. As a control, cells were activated with a 1∶50 dilution of ascites fluid of CD3 mAb MEM92 (second panel). Postnuclear lysates were processed for western blotting using the indicated phosphospecific antibodies. Western blotting using an anti-actin antibody was performed as loading control.CC BY · PubMed Central
Figure 4 Cytokine production upon conventional and superagonistic CD28 stimulation of human T cells. 5×104 freshly prepared human T-cells/96-well were stimulated with the indicated combination of antibodies as described in Fig. 1A or were left untreated as controls. At 48 hours 50 µl culture supernatant was removed from each well. Supernatants obtained from 3 wells were pooled and cytokine content was determined using the Cytokine Bead Array from BD in signals per minute [spm] (black bars). Additionally, induction of T cell proliferation was monitored upon treatment with the indicated antibody combinations (gray bars). 72 hours after stimulation, cultures were pulsed with 3H-thymidine for 6 hours, then harvested and proliferation analyzed by counts per minute [cpm]. Data represent the mean of 5 individual experiments.
Figure 4 Cytokine production upon conventional and superagonistic CD28 stimulation of human T cells. 5×104 freshly prepared human T-cells/96-well were stimulated with the indicated combination of antibodies as described in Fig. 1A or were left untreated as controls. At 48 hours 50 µl culture supernatant was removed from each well. Supernatants obtained from 3 wells were pooled and cytokine content was determined using the Cytokine Bead Array from BD in signals per minute [spm] (black bars). Additionally, induction of T cell proliferation was monitored upon treatment with the indicated antibody combinations (gray bars). 72 hours after stimulation, cultures were pulsed with 3H-thymidine for 6 hours, then harvested and proliferation analyzed by counts per minute [cpm]. Data represent the mean of 5 individual experiments.CC BY · PubMed Central
Figure 5 Analysis of the signaling pathways controlling CD28SA-mediated IFN-γ and IL-2 production. (A) Short term IFN-γ production upon CD28SA stimulation of T cells. 1×106 T cells/200 µl were activated by CD28SA ANC28.1 as described for Figs. 1 –4. At the indicated time points 50 µl of the supernatants were removed, diluted 1∶3 v/v, and the concentration of secreted IFN-γ was determined using a commercially available ELISA. (B) Molecular requirements determining CD28SA-mediated IFN-γ production. T cells were pretreated for 30 minutes with the indicated substances prior to stimulation with ANC28.1. EGTA was used at 1 mM, CaCl2 at 2 mM, cycloheximide at 50 µg/ml, CSA at 150 ng/ml, PP2 at 10 µM, Wortmannin at 0.1 µM, and Ly294002 at 20 µM. At the indicated time points cytokine production was determined as described in (A). (C) 1×106 freshly prepared human T cells/lane were stimulated with 10 µg/ml ANC28.1 followed by crosslinking with 20 µg/ml polyclonal goat anti-mouse antiserum with or without Wortmannin treatment. Western blotting was conducted as described in Fig. 3. Note that identical results were obtained when T cells were pretreated with LY294002 (data not shown). (D) Molecular requirements determining CD28SA-mediated IL-2 production. T cells were pretreated for 30 minutes with the indicated substances prior to stimulation with ANC28.1 as described in (B). 4 h after stimulation 50 µl of the supernatants were removed, diluted 1∶3 v/v, and the concentration of IL-2 was analyzed in supernatants by an ELISA. (E) CD28SA-mediated IFN-γ and IL-2 production requires sustained Ca++-flux. T cells were stimulated with ANC28.1 as described above. At 15′, 30′, 1 h, 2 h, 3 h, 4 h, and 5 h Ca++-flux was interrupted by addition of EGTA (1 mM) and the concentration of the cytokines in the supernatant was determined as described in (B) and (D). The concentrations of IL-2 and IFN-γ that were produced by ANC28.1-stimulated T cells following 6 hours of stimulation in the absence of EGTA were set to 100%. All data shown in Fig. 5 are representative for three independently performed experiments.
Figure 5 Analysis of the signaling pathways controlling CD28SA-mediated IFN-γ and IL-2 production. (A) Short term IFN-γ production upon CD28SA stimulation of T cells. 1×106 T cells/200 µl were activated by CD28SA ANC28.1 as described for Figs. 1 –4. At the indicated time points 50 µl of the supernatants were removed, diluted 1∶3 v/v, and the concentration of secreted IFN-γ was determined using a commercially available ELISA. (B) Molecular requirements determining CD28SA-mediated IFN-γ production. T cells were pretreated for 30 minutes with the indicated substances prior to stimulation with ANC28.1. EGTA was used at 1 mM, CaCl2 at 2 mM, cycloheximide at 50 µg/ml, CSA at 150 ng/ml, PP2 at 10 µM, Wortmannin at 0.1 µM, and Ly294002 at 20 µM. At the indicated time points cytokine production was determined as described in (A). (C) 1×106 freshly prepared human T cells/lane were stimulated with 10 µg/ml ANC28.1 followed by crosslinking with 20 µg/ml polyclonal goat anti-mouse antiserum with or without Wortmannin treatment. Western blotting was conducted as described in Fig. 3. Note that identical results were obtained when T cells were pretreated with LY294002 (data not shown). (D) Molecular requirements determining CD28SA-mediated IL-2 production. T cells were pretreated for 30 minutes with the indicated substances prior to stimulation with ANC28.1 as described in (B). 4 h after stimulation 50 µl of the supernatants were removed, diluted 1∶3 v/v, and the concentration of IL-2 was analyzed in supernatants by an ELISA. (E) CD28SA-mediated IFN-γ and IL-2 production requires sustained Ca++-flux. T cells were stimulated with ANC28.1 as described above. At 15′, 30′, 1 h, 2 h, 3 h, 4 h, and 5 h Ca++-flux was interrupted by addition of EGTA (1 mM) and the concentration of the cytokines in the supernatant was determined as described in (B) and (D). The concentrations of IL-2 and IFN-γ that were produced by ANC28.1-stimulated T cells following 6 hours of stimulation in the absence of EGTA were set to 100%. All data shown in Fig. 5 are representative for three independently performed experiments.CC BY · PubMed Central
Figure 6 Despite similar TGN1412 binding, Macaca derived T cells show reduced calcium flux upon TGN1412 stimulation when compared to human T cells. (A) MACS purified CD3+ human T cells (stained with an anti-CD3-APC antibody) and CD3+ monkey T cells (stained with an anti-CD3-PE antibody) were mixed 1∶1 and then incubated with graded concentrations of Alexa 488 labeled TGN1412. Binding of TGN1412-Alexa 488 was monitored by FACS analysis. Numbers given indicate the mean fluorescence intensity of samples. (B) Ratio of CD4+ vs. CD8+ T cells (gated on CD3+ cells) of human and monkey blood samples was analyzed by FACS analyses. (C) 1×106 freshly isolated Indo-1 loaded M. fascicularis and M. mulatta T cells were treated as described in Fig. 2 using the superagonistic CD28 specific mAb TGN1412 (10 µg/ml; red triangle). For crosslinking, 20 µg/ml monoclonal mouse anti-human IgG4 was used (black triangle) and induction of the Ca++-response was monitored. To confirm viability of cells and proper loading with Indo-1, Ionomycin (10 µg/ml) was added at the end of the experiment (unfilled triangle).
Figure 6 Despite similar TGN1412 binding, Macaca derived T cells show reduced calcium flux upon TGN1412 stimulation when compared to human T cells. (A) MACS purified CD3+ human T cells (stained with an anti-CD3-APC antibody) and CD3+ monkey T cells (stained with an anti-CD3-PE antibody) were mixed 1∶1 and then incubated with graded concentrations of Alexa 488 labeled TGN1412. Binding of TGN1412-Alexa 488 was monitored by FACS analysis. Numbers given indicate the mean fluorescence intensity of samples. (B) Ratio of CD4+ vs. CD8+ T cells (gated on CD3+ cells) of human and monkey blood samples was analyzed by FACS analyses. (C) 1×106 freshly isolated Indo-1 loaded M. fascicularis and M. mulatta T cells were treated as described in Fig. 2 using the superagonistic CD28 specific mAb TGN1412 (10 µg/ml; red triangle). For crosslinking, 20 µg/ml monoclonal mouse anti-human IgG4 was used (black triangle) and induction of the Ca++-response was monitored. To confirm viability of cells and proper loading with Indo-1, Ionomycin (10 µg/ml) was added at the end of the experiment (unfilled triangle).CC BY · PubMed Central

Verification

Claims the paper makes

8 Valid · 3 Not valid · 33 Not checked · 105 Own results and interpretations

86 more claims · 1 with their cited sources checked

Create a free account to see all 149 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 22
  • Not yet classified. 20
  • Probably not a substantial claim. 22
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 46 references

Cited by

See all 79

Metadata

Authors
Waibler, Z., Sender, L. Y., Merten, C., Hartig, R., Kliche, S., Gunzer, M., Reichardt, P., Kalinke, U., & Schraven, B.
Affiliations
  • Paul Ehrlich Institut (DE)
  • Otto-von-Guericke-Universität Magdeburg (DE)
Corresponding author
  • Kalinke, Ulrich
  • Schraven, Burkhart
Venue
PLoS ONE
Published
2008-03-05
Volume
3
Issue
3
Pages
e1708
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2044984824
Cited by
79
References
46
Citations by year
2026: 4 · 2025: 1 · 2022: 1 · 2021: 4 · 2020: 2 · 2019: 4 · 2018: 4 · 2017: 4 · 2016: 10 · 2015: 3 · 2014: 7 · 2013: 2 · 2012: 8
FWCI
3.48
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
Deutsche Forschungsgemeinschaft (SFB 432)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
Keywords
TGN1412, T cell activation, calcium signaling, interferon-gamma, TNF-α, interleukin-2, Src kinase, phosphatidylinositol 3-kinase, regulatory T cells, autoimmune disease therapy, adverse drug reactions, CD4+ T cells
MeSH terms
Animals, Antibodies, Monoclonal, Calcium, Flow Cytometry, Humans, Interferon-gamma, Interleukin-2, Lymphocyte Activation, Macaca fascicularis, Macaca mulatta, Quinuclidines, T-Lymphocytes, Tumor Necrosis Factor-alpha, Blotting, Western, Signal Transduction, CD28 Antigens, src-Family Kinases, Cell Proliferation, T-Lymphocytes, Regulatory, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies. https://app.cochat.ai/papers/10.1371/journal.pone.0001708
The paper
Waibler, Z., Sender, L. Y., Merten, C., Hartig, R., Kliche, S., Gunzer, M., Reichardt, P., Kalinke, U., & Schraven, B. (2008). Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies. PLoS ONE. https://doi.org/10.1371/journal.pone.0001708

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.